CP1.AU · CannPal Animal Therapeutics Limited

-

Please sign in to comment on CP1.AU

1 Comment

Admin

4 years, 1 month ago

CannPal Animal Therapeutics Limited is currently in a long term uptrend where the price is trading 16.6% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

CannPal Animal Therapeutics Limited's total revenue rose by 8.5% to $756K since the same quarter in the previous year.

Its net income has increased by 46.8% to $-273K since the same quarter in the previous year.

Finally, its free cash flow grew by 43.0% to $-252K since the same quarter in the previous year.

Based on the above factors, CannPal Animal Therapeutics Limited gets an overall score of 5/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	AU
CurrencyCode	AUD
ISIN	AU000000CP17

PE Ratio	None
Beta	1.05
Market Cap	16M
Target Price	None
Dividend Yield	0.0%

ABOUT

CannPal Animal Therapeutics Limited

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia. As of March 11, 2021, CannPal Animal Therapeutics Limited operates as a subsidiary of AusCann Group Holdings Ltd.

CP1.AU · CannPal Animal Therapeutics Limited

-

CannPal Animal Therapeutics Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest CannPal Animal Therapeutics Limited using a moving average strategy